Insulin Resistance & Hypertension — USA & U --bg: #f5f5f3;K 1975–2022

Insulin Resistance & Hypertension

Prevalence trajectories in the USA and United Kingdom, 1975–2022. Of all the conditions in this series, hypertension has the most directly documented causal mechanism: insulin resistance drives sodium retention in the kidneys, raises sympathetic nervous system activity, and promotes arterial stiffness — all independently raising blood pressure. The correlation is exceptionally strong in both countries and the mechanistic pathway is among the best-established in metabolic medicine.

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as that particular disease. This curve can rise more steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not manifest this condition until their 50s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed cases years later.

The r value (e.g. r = 0.97) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.97 means that 97% of the rise in this condition over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

United States

USA — Insulin Resistance vs Hypertension

1975 – 2022  |  % of adults
Insulin Resistance (%)
Hypertension (%)
United Kingdom

UK — Insulin Resistance vs Hypertension

1975 – 2022  |  % of adults
Insulin Resistance (%)
Hypertension (%)
r = 0.97
USA
IR ↔ Hypertension
r = 0.95
UK
IR ↔ Hypertension
~48%
USA adults with
hypertension (2022)
~30%
UK adults with
hypertension (2022)
Why the USA and UK numbers differ: The USA figure (~48%) uses the 2017 ACC/AHA guideline threshold of ≥130/80 mmHg, adopted in 2017. The UK figure (~30%) uses the older NICE/NHS threshold of ≥140/90 mmHg, which is still the standard in England. If the same 130/80 threshold were applied to the UK, the figure would be considerably higher — likely 40%+. This is a measurement standard difference, not a real health difference. Both populations show the same underlying trend: rising in parallel with insulin resistance over 50 years.
The mechanistic pathway is the most direct of any condition in this series: Insulin resistance → compensatory hyperinsulinaemia → kidneys retain sodium (via ENaC stimulation) → expanded blood volume → raised blood pressure. Simultaneously, elevated insulin activates the sympathetic nervous system, raising heart rate and vascular resistance. High insulin also promotes smooth muscle proliferation in arterial walls → arterial stiffness → sustained hypertension. This is not a coincidental association — it is a well-established causal sequence documented in multiple intervention studies. Reversing insulin resistance through dietary change (low-carbohydrate, intermittent fasting) consistently lowers blood pressure independent of weight loss. Sources: DeFronzo & Ferrannini (1991); Landsberg (2012); Reaven (1988); UKPDS; multiple RCTs.
Data sources
Hypertension USA — prevalence trend: NHANES historical series. Egan et al. JAMA 2010 — trends 1988–2008. NCHS Data Brief No. 364 (2020) — 30.7% by old threshold / 45.4% by 2017 threshold in 2017–18. NCHS Data Brief No. 511 (2024) — 47.7% adults 2021–2023. CDC Million Hearts Hypertension Cascade data. Pre-1988 estimates from NCD-RisC pooled global analysis 1975–2015 (Lancet 2016) and Kannel et al. Framingham Heart Study data.
https://www.cdc.gov/nchs/data/databriefs/db364-h.pdf
https://www.cdc.gov/nchs/products/databriefs/db511.htm
https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html
Hypertension UK — prevalence trend: NHS Health Survey for England (HSE) annual series 2003–2022 (NHS Digital). Graham et al. BMJ Medicine 2025 — HSE trend analysis 2003–2021: ~31% in 2003, stable 28–30% thereafter. PHE Hypertension Prevalence Estimates 2017. Pre-2003 estimates from NCD-RisC Lancet 2016 pooled analysis and UK Biobank historical data.
https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2022-part-2/adult-health
https://pmc.ncbi.nlm.nih.gov/articles/PMC12666190/
https://assets.publishing.service.gov.uk/media/5e725883e90e070aca43cc9d/Summary_of_hypertension_prevalence_estimates_in_England__1_.pdf
Mechanistic evidence — IR causes hypertension: DeFronzo RA & Ferrannini E. Insulin resistance: a multifaceted syndrome. Diabetes Care 1991. Reaven GM. Banting Lecture 1988 — role of insulin resistance in human disease. Landsberg L. Insulin-mediated sympathetic stimulation. J Hypertension 2012. Multiple RCTs showing low-carbohydrate diets reduce blood pressure independently of weight loss.
Insulin Resistance USA & UK: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); NHS Health Survey England; GBD 2019 metabolic risk; Diabetes UK; Frontiers meta-analysis 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://www.diabetesuk.org/professionals/position-statements-reports/statistics/
Scroll to Top
MENU
For Radiant Health